Ocular Toxicities Associated with ADCs and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management

Featuring an interview with Dr Neel Pasricha, including the following topics:

• Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00)
• Association of corneal toxicities with ADCs (4:56)
• Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02)
• Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44)
• Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55)
• Other ocular toxicities associated with cancer therapies (24:26)
• Prevention and management of corneal toxicity (33:58)
• Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39)
• General clinical pearls on the management of ocular toxicities with cancer therapies (48:04)

CME information and select publications